Suzuken : Notice Concerning Change of Major Shareholder
November 14, 2023
Share
November 14, 2023
Press Release SUZUKEN CO., LTD.
Shigeru Asano, President and CEO (Stock Code: 9987)
Securities Traded: Prime Markets of the Tokyo and Nagoya Stock Exchanges, and the Sapporo Securities Exchange
Contact: Yuichi Yamamoto, Executive Officer, Senior General Manager of Corporate Group Planning Headquarters
Tel.: +81-52-961-2331
Notice Concerning Change of Major Shareholder
Suzuken Co., Ltd. (hereinafter, "the Company") hereby announces a change in one of its major shareholders on
November 10, 2023.
1. Circumstances Leading to the Change
On November 13, 2023, the following shareholder submitted a Large Shareholding Report (Change Report) to the
Kanto Local Finance Bureau, by which means the Company confirmed the change of this major shareholder.
2. Outline of the Changed Shareholder
(1) Name
Silchester International Investors LLP
(2) Address
5F Time & Life Building, 1 Bruton Street, London W1J 6TL,
United Kingdom
(3) Name and Title of Representative
Timothy Linehan, Partner
(4) Business Profile
Investment advisory business
3. Number of Voting Rights Held by the Shareholder in Question (Number of the Shares Held) and Ratio to the Number of Voting Rights of All Shareholders
Number of voting rights
Ratio to the number of voting rights of
(Number of shares held)
all shareholders
Before change
85,956
10.39%:Note 2
(as of September 27, 2023)
(8,595,600 shares)
After change
77,169
9.32%:Note 2
(as of November 10, 2023)
(7,716,900 shares)
Note 1: The above is written on the basis of the Large Shareholding Report (Change Report) submitted by the shareholder in question. It does not represent a confirmation by the Company of the actual number of shares held in the name of the shareholder in question.
The ranking of major shareholders has not been confirmed, and therefore is not indicated here.
Note 2: The ratio to the number of voting rights of all shareholders as of September 27, 2023 was calculated on the basis of a total number of voting rights of all shareholders of 827,658, which is based on the total number of issued shares as of September 27, 2023 (82,831,904) minus the number of treasury shares held by the Company as of September 27, 2023 (66,063).
The ratio to the number of voting rights of all shareholders as of November 10, 2023 was calculated on the basis of a total number of voting rights of all shareholders of 827,658, which is based on the total number of issued shares as of November 10, 2023 (82,831,904) minus the number of treasury shares held by the Company as of November 10, 2023 (66,063).
Note 3: The ratio to the number of voting rights of all shareholders is rounded to the second decimal place.
4. Future Outlook
This matter is based on the Change Report in the Large Shareholding Report. There are no specific details to be mentioned regarding the future outlook.
This is an English translation of a statement written initially in Japanese and is provided for reference purposes only. The Japanese original shall prevail in the event of any discrepancy between this document and the original.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Suzuken Co. Ltd. published this content on 14 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 November 2023 01:57:06 UTC.
Suzuken Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in four business segments. The Pharmaceutical Wholesale segment sells pharmaceuticals, diagnostic drugs, and medical equipment and materials, among others. The Pharmaceutical Manufacturing segment manufactures pharmaceuticals and diagnostic drugs and others. The Insurance Pharmacy segment is engaged in dispensing operations based on prescriptions from medical institutions. The Medical-related Service and Others segment is engaged in the provision of manufacturer support services, such as the transportation of medicines and comprehensive support for the distribution of drugs for rare diseases; the nursing services; the manufacture of physiological examination equipment, such as electrocardiographic monitors and blood pressure monitors; as well as other services, such as the sale of medical books.